Biomedical applications of bisphosphonates EV Giger, B Castagner, JC Leroux Journal of Controlled Release 167 (2), 175-188, 2013 | 218 | 2013 |
Synthetically defined glycoprotein vaccines: current status and future directions R Adamo, A Nilo, B Castagner, O Boutureira, F Berti, GJL Bernardes Chemical science 4 (8), 2995-3008, 2013 | 180 | 2013 |
Streamlined access to conjugation-ready glycans by automated synthesis L Kröck, D Esposito, B Castagner, CC Wang, P Bindschädler, ... Chemical Science 3 (5), 1617-1622, 2012 | 168 | 2012 |
Automated synthesis of the tumor-associated carbohydrate antigens Gb-3 and Globo-H: incorporation of α-galactosidic linkages DB Werz, B Castagner, PH Seeberger Journal of the American Chemical Society 129 (10), 2770-2771, 2007 | 167 | 2007 |
Gene delivery with bisphosphonate-stabilized calcium phosphate nanoparticles EV Giger, J Puigmartí-Luis, R Schlatter, B Castagner, PS Dittrich, ... Journal of Controlled Release 150 (1), 87-93, 2011 | 142 | 2011 |
Activatable cell penetrating peptide–peptide nucleic acid conjugate via reduction of azobenzene PEG chains SH Lee, E Moroz, B Castagner, JC Leroux Journal of the American Chemical Society 136 (37), 12868-12871, 2014 | 125 | 2014 |
A natural polyphenol exerts antitumor activity and circumvents anti–PD-1 resistance through effects on the gut microbiota M Messaoudene, R Pidgeon, C Richard, M Ponce, K Diop, M Benlaifaoui, ... Cancer Discovery 12 (4), 1070-1087, 2022 | 113 | 2022 |
Well-defined multivalent ligands for hepatocytes targeting via asialoglycoprotein receptor X Huang, JC Leroux, B Castagner Bioconjugate chemistry 28 (2), 283-295, 2017 | 111 | 2017 |
Is there a future for cell-penetrating peptides in oligonucleotide delivery? SH Lee, B Castagner, JC Leroux European Journal of Pharmaceutics and Biopharmaceutics 85 (1), 5-11, 2013 | 103 | 2013 |
Combined approaches to the synthesis and study of glycoproteins GJL Bernardes, B Castagner, PH Seeberger ACS Chemical Biology 4 (9), 703-713, 2009 | 102 | 2009 |
Automated solid‐phase synthesis of protected oligosaccharides containing β‐mannosidic linkages JDC Codée, L Kröck, B Castagner, PH Seeberger Chemistry–A European Journal 14 (13), 3987-3994, 2008 | 97 | 2008 |
Synthesis of a sialic acid α (2− 3) galactose building block and its use in a linear synthesis of sialyl Lewis X S Hanashima, B Castagner, D Esposito, T Nokami, PH Seeberger Organic letters 9 (9), 1777-1779, 2007 | 82 | 2007 |
Targeting bacterial toxins ME Ivarsson, JC Leroux, B Castagner Angewandte Chemie International Edition 51 (17), 4024-4045, 2012 | 76 | 2012 |
siRNA transfection with calcium phosphate nanoparticles stabilized with PEGylated chelators EV Giger, B Castagner, J Räikkönen, J Mönkkönen, JC Leroux Advanced healthcare materials 2 (1), 134-144, 2013 | 74 | 2013 |
Immune modulation by Lacto-N-fucopentaose III in experimental autoimmune encephalomyelitis B Zhu, S Trikudanathan, AL Zozulya, C Sandoval-Garcia, JK Kennedy, ... Clinical immunology 142 (3), 351-361, 2012 | 73 | 2012 |
siRNA nanocarriers based on methacrylic acid copolymers AE Felber, B Castagner, M Elsabahy, GF Deleavey, MJ Damha, ... Journal of Controlled Release 152 (1), 159-167, 2011 | 72 | 2011 |
Modular design of redox-responsive stabilizers for nanocrystals K Fuhrmann, A Połomska, C Aeberli, B Castagner, MA Gauthier, ... ACS nano 7 (9), 8243-8250, 2013 | 61 | 2013 |
Reduction of olefins on solid support using diimide P Lacombe, B Castagner, Y Gareau, R Ruel Tetrahedron letters 39 (38), 6785-6786, 1998 | 49 | 1998 |
Characterization of calcium phosphate nanoparticles based on a PEGylated chelator for gene delivery X Huang, D Andina, J Ge, A Labarre, JC Leroux, B Castagner ACS applied materials & interfaces 9 (12), 10435-10445, 2017 | 47 | 2017 |
Inhibition of vascular calcification by inositol phosphates derivatized with ethylene glycol oligomers AE Schantl, A Verhulst, E Neven, GJ Behets, PC D’Haese, M Maillard, ... Nature communications 11 (1), 721, 2020 | 46 | 2020 |